Want to join the conversation?
$QGEN said no meaningful revenue contribution from GeneReader NGS System were included in its 2016 financial forecasts. Company also does not expect a material impact from the court's decision on its full-year 2016 outlook nor anticipates any material changes to its internal 2017 projections. A trial date in the case is scheduled for Nov. 2017.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.